Physician profile
Yang Liu
NPI 1922260504
$4,428.59
in general payments reported to CMS, 2019-2025
49 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $67.27 · 2021: $158 · 2022: $306 · 2023: $173 · 2024: $1,307 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,569 · Education: $95.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.98 |
| Education | $95.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $510.52 | 2021-2025 | Tagrisso, Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $472.55 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Daiichi Sankyo INC. | $440.80 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $307.50 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Janssen Biotech, INC. | $292.73 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $207.74 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Genentech USA, INC. | $187.07 | 2019-2025 | Polivy, Tecentriq, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $184.82 | 2021-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $168.44 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $110.87 | 2019-2025 | Keytruda, Keytruda Qlex |
| Aveo Pharmaceuticals, INC. | $107.89 | 2024-2025 | |
| Foundation Medicine, INC. | $97.69 | 2019 | |
| Seagen INC. | $95.00 | 2021 | |
| Taiho Oncology, INC. | $61.82 | 2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.